Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.50    -1.00 (-1.40%)
Bid:
70.00
Ask:
71.00
Spread: 1.00 (1.429%)
Market Cap: £320.85m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Total Voting Rights

21 Dec 2006 08:44

Avacta Group plc (the "Company")

Total Voting Rights

In conformity with the Transparency Directive's transitional provision 6, the Company notifies the market of the following:

As at the date of this announcement, the Company's issued share capital consists of 669,327,342 ordinary shares with a nominal value of 0.1 pence each ("Ordinary Shares"), with voting rights. The Company does not hold any Ordinary Shares in Treasury.

Therefore, the total number of Ordinary Shares with voting rights is 669,327,342.

The above figure of 669,327,342 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

Enquiries:Avacta Group plc 0870 835 4367 Tim Sykes, Chief Financial Officer Nexus Financial Ltd 020 7451 7068 Nicholas Nelson WH Ireland Limited 0161 832 2174 David Youngman

AVACTA GROUP PLC
Date   Source Headline
19th Jul 20163:13 pmRNSHolding(s) in Company
19th Jul 20167:15 amRNSHardman report: New Affimer opportunities
14th Jul 20167:00 amRNSCollaboration with Glythera
8th Jul 20167:00 amRNSDirector/PDMR Shareholding
22nd Jun 20167:00 amRNSAffimer Binders for Zika Virus Diagnostics
16th Jun 201611:08 amRNSIssue of Equity
13th Jun 20167:00 amRNSCollaboration with Mologic
29th Apr 20163:04 pmRNSDirector's Dealing
25th Apr 20167:00 amRNSHalf-year Report
19th Apr 20167:00 amRNSAffimer Therapeutic Platform Development Milestone
7th Apr 20167:00 amRNSDirector's Dealing
5th Apr 20167:00 amRNSInvestor Evening
15th Mar 20167:00 amRNSIssue of Equity
7th Mar 20167:00 amRNSAvacta Establishes Scientific Advisory Board
25th Feb 20164:34 pmRNSHolding(s) in Company
24th Feb 20167:00 amRNSGrant Funding Awarded
23rd Feb 201610:54 amRNSHardman & Co Issues Research Report
23rd Feb 20167:00 amRNSDirector's Dealing
17th Feb 20167:00 amRNSDirectors' Dealings and Issue of Equity
26th Jan 20168:05 amRNSShare Consolidation
25th Jan 20163:35 pmRNSResult of Annual General Meeting
25th Jan 20167:01 amRNSPre-close trading update
25th Jan 20167:00 amRNSPhilippe Cotrel Appointed Chief Commercial Officer
21st Jan 20167:00 amRNSProposed Shareholder Consolidation
7th Jan 20167:00 amRNSPosting of Annual Report & Accounts and AGM Notice
5th Jan 20167:00 amRNSIssue of Equity
10th Dec 20157:00 amRNSAppointment of Tony Gardiner as CFO
1st Dec 20154:44 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSIssue of Equity
23rd Nov 20157:00 amRNSIssue of Equity
6th Nov 201510:56 amRNSHolding(s) in Company
30th Oct 20157:00 amRNSIssue of Equity
26th Oct 20157:00 amRNSFinal Results
19th Oct 20157:00 amRNSAffimers improve disease resistance in plants
9th Oct 20157:00 amRNSRobust performance of Affimers on Luminex platform
8th Oct 20157:00 amRNSNotice of Results
17th Sep 20157:00 amRNSAppoints Dr Mike Owen as Non-executive Director
10th Sep 20157:00 amRNSTotal Voting Rights
3rd Sep 20157:00 amRNSIssue of Equity
5th Aug 201510:00 amRNSHolding(s) in Company
5th Aug 20157:00 amRNSHolding(s) in Company
4th Aug 201510:18 amRNSIssue of Equity
31st Jul 201510:42 amRNSResult of General Meeting
23rd Jul 20157:00 amRNSIssue of Equity
15th Jul 20157:00 amRNSConditional Placing to Raise up to £22.0 Million
7th Jul 20158:00 amRNSBoard Change
7th Jul 20157:00 amRNSPre-Close Trading Update
20th May 201511:48 amRNSHolding(s) in Company
19th May 201512:42 pmRNSHolding(s) in Company
11th May 20157:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.